Cholesteryl ester transfer protein (CETP) inhibitors

British Journal of Cardiology

Volumn 19, Issue 3, 2012, Pages 126-133

  Durrington, Paul N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Atherosclerosis; Cholesteryl ester transfer proteins; High density lipoproteins; Lipid lowering drugs; Lipoproteins

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHYLOMICRON; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 CYSTEINE]; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; SCAVENGER RECEPTOR BI; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTERY WALL; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DRUG EFFICACY; DRUG MECHANISM; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; OUTCOME ASSESSMENT; OXIDATION; REVIEW;

EID: 84866180002     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: 10.5837/bjc.2012.024     Document Type: Review

References (51)

1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81. http://dx.doi.org/10.1016/S0140-6736(10)61350-5
2. Chaudhury M. Blood analytes. In: Sproston K, Primatesta P, eds. Health Survey for England 2003: risk factors for cardiovascular disease. London: The Stationery Office, 2004:241-87.
3. Durrington PN. Hyperlipidaemia diagnosis and management. 3rd ed. London: Hodder Arnold, 2008.
4. Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 2008;9:2145-60. http://dx.doi.org/10. 1517/14656566.9.12.2145
5. Ara R, Pandor A, Tumur I et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther 2008;30:1508-23. http://dx.doi.org/10.1016/j.clinthera.2008.08.002
6. Huijgen R, Abbink EJ, Bruckert E et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010; 32 :615-25. http://dx.doi.org/10.1016/j. clinthera.2010.04.014
7. Rader DJ, Alexander ET, Weibel GL et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(suppl):S189-S194. http://dx.doi.org/10.1194/jlr.R800088-JLR200
8. Anderson KM, Wilson PW, Odell PM et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
9. Lai E, De Lepeleire I, Crumley TM et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849-57. http://dx.doi.org/10.1038/sj.clpt.6100180
10. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-15. http://dx.doi.org/10.1056/NEJMoa031766
11. Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14. http://dx.doi.org/10.1016/S0140-6736(07)61813-3
12. Stein EA, Roth EM, Rhyne JM et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8. http://dx.doi.org/10.1093/eurheartj/ehp601
13. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15. http://dx.doi.org/10.1056/NEJMoa1009744
14. Myant N. The biology of cholesterol and related steroids. London: William Heinemann Medical Books Ltd., 1981.
15. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;1:16-19. http://dx.doi.org/10.1016/S0140-6736(75)92376-4
16. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol 2008;93:27-42.
17. Schaefer EJ, Santos RD, Asztalos BF. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 2010;21:289-97. http://dx.doi.org/10. 1097/MOL.0b013e32833c1ef6
18. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009;116:87-98. http://dx.doi.org/10.1042/CS20080106
19. Chapman MJ, Le GW, Guerin M et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010;31:149-64. http://dx.doi.org/10.1093/eurheartj/ehp399
20. Khera AV, Cuchel M, Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364 :127-35. http://dx.doi.org/10.1056/NEJMoa1001689
21. Duverger N, Kruth H, Emmanuel F et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996;94:713-17.
22. Plump AS, Azrolan N, Odaka H et al. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res 1997;38:1033-47.
23. Nicholls SJ. High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials. Am J Cardiol 2009;104:16E-21E. http://dx.doi.org/10.1016/j.amjcard.2009.09.015
24. Feng Y, Lievens J, Jacobs F et al. Hepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosis. Cardiovasc Res 2010;88:376-85. http://dx.doi.org/10.1093/cvr/ cvq204
25. Channon KM, Clegg RJ, Bhatnagar D et al. Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer. Atherosclerosis 1990;80:217-26. http://dx.doi.org/10.1016/0021-9150(90)90029-I
26. Masson D, Jiang XC, Lagrost L et al. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 2009;50(suppl):S201-S206. http://dx.doi.org/10.1194/jlr.R800061-JLR200
27. Barter PJ, Brewer HB Jr., Chapman MJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7. http://dx.doi.org/10.1161/01.ATV. 0000054658.91146.64
28. Langer C, Huang Y, Cullen P et al. Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. J Mol Med 2000;78:217-27. http://dx.doi.org/10.1007/s001090000096
29. Younis NN, Soran H, Sharma R et al. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res 2010;7:289-95. http://dx.doi.org/10.1177/1479164110383063
30. Soran H, Younis NN, Charlton-Menys V et al. Variation in paraoxonase-1 and atherosclerosis. Curr Opin Lipidol 2009;20:265-74. http://dx.doi.org/10. 1097/MOL.0b013e32832ec141
31. Bhattacharyya T, Nicholls SJ, Topol EJ et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76. http://dx.doi.org/10. 1001/jama.299.11.1265
32. Besler C, Heinrich K, Rohrer L et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-708. http://dx.doi.org/10.1172/JCI42946
33. Bhatnagar D, Durrington PN, Channon KM et al. Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis 1993;98:25-32. http://dx.doi.org/10.1016/0021-9150(93) 90220-O
34. Caslake MJ, Stewart G, Day SP et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003;171:245-53. http://dx.doi.org/10.1016/j. atherosclerosis.2003.08.025
35. Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-9. http://dx.doi.org/10.1016/S0140-6736(10)60545-4
36. Bellanger N, Orsoni A, Julia Z et al. Atherogenic reverse cholesterol transport pathway is defective in familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol 2011; 31:1675-81. http://dx.doi.org/10.1161/ATVBAHA.111.227181
37. Ballantyne CM, Olsson AG, Cook TJ et al. Influence of low highdensity lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51. http://dx.doi.org/10.1161/hc5001.100624
38. Charlton-Menys V, Durrington P. Apolipoproteins AI and B as therapeutic targets. J Intern Med 2006;259:462-72. http://dx.doi.org/10.1111/j.1365-2796. 2006.01646.x
39. Camejo G, Hurt-Camejo E, Wiklund O et al. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998;139:205-22. http://dx.doi.org/10.1016/ S0021-9150(98)00107-5
40. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009;104:10E-15E. http://dx.doi.org/10.1016/j.amjcard.2009. 09.014
41. Vergeer M, Bots ML, van Leuven SI et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515-22. http://dx.doi.org/10.1161/ CIRCULATIONAHA.108.772665
42. Robinson JG. Dalcetrapib: a review of Phase II data. Expert Opin Investig Drugs 2010;19:795-805. http://dx.doi.org/10.1517/13543784.2010.488219
43. Niesor EJ, Magg C, Ogawa N et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-54. http://dx.doi.org/ 10.1194/jlr.M008706
44. Nicholls SJ, Brewer HB, Kastelein JJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099-109. http://dx.doi.org/10.1001/jama.2011.1649
45. Cao G, Beyer TP, Zhang Y et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011;52:2169-76. http://dx.doi.org/10.1194/jlr.M018069
46. Morton RE, Greene DJ. Partial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma. Atherosclerosis 2007;192:100-07. http://dx.doi.org/10.1016/j.atherosclerosis.2006.06.030
47. Fayad ZA, Mani V, Woodward M et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59. http://dx.doi.org/10.1016/S0140-6736(11)61383-4
48. Schwartz GG, Olsson AG, Ballantyne CM et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901. http://dx.doi.org/10.1016/ j.ahj.2009.09.017
49. Kozarsky KF, Donahee MH, Glick JM et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000;20:721-7. http://dx.doi.org/10.1161/01.ATV.20.3.721
50. Lopez D, Sanchez MD, Shea-Eaton W et al. Estrogen activates the high-density lipoprotein receptor gene via binding to estrogen response elements and interaction with sterol regulatory element binding protein-1A. Endocrinology 2002;143:2155-68. http://dx.doi.org/10.1210/en.143.6.2155
51. Gurfinkel R, Joy TR. Anacetrapib: hope for CETP inhibitors? Cardiovasc Ther 2010;29:327-39. http://dx.doi.org/10.1111/j.1755-5922.2010.00142.x